Jan B. Vermorken

Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)

Gordon John Sampson Rustin, Ignace Vergote, Elizabeth A. Eisenhauer et al. · International Journal of Gynecological Cancer · 2011 · 600 citations

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

Jan B. Vermorken, A.M.E. Claessen, Harm van Tinteren et al. · The Lancet · 1999 · 502 citations · Full text

Tumor Immunology, Cancer Immunosurveillance, Stage Ii +10

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)

Andreas du Bois, Michael Quinn, Tate Thigpen et al. · Annals of Oncology · 2005 · 465 citations

Medicine, Cancer Management, Reproductive Health +9

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

Jan B. Vermorken, Jan Stöhlmacher-Williams, Lisa Licitra et al. · The Lancet Oncology · 2013 · 432 citations · Full text

Metastatic Squamous-cell Carcinoma, Open-label Phase 3, Medicine +8

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

Jean-Pascal H. Machiels, Robert I. Haddad, Jérôme Fayette et al. · The Lancet Oncology · 2015 · 386 citations

Neoadjuvant Therapy, Neck 1, Randomised Phase 3 +10